Rheos Capital Works Inc. Has $26.53 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Rheos Capital Works Inc. boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 19.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 51,000 shares of the medical research company’s stock after acquiring an additional 8,300 shares during the period. Thermo Fisher Scientific accounts for about 1.5% of Rheos Capital Works Inc.’s holdings, making the stock its 19th biggest position. Rheos Capital Works Inc.’s holdings in Thermo Fisher Scientific were worth $26,532,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC bought a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth $26,000. Peterson Financial Group Inc. bought a new position in shares of Thermo Fisher Scientific in the third quarter valued at $27,000. Missouri Trust & Investment Co bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $29,000. Endeavor Private Wealth Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $30,000. Finally, Decker Retirement Planning Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $43,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TMO. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a report on Friday, January 10th. Royal Bank of Canada reduced their target price on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. TD Cowen increased their price objective on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Finally, StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $655.64.

Thermo Fisher Scientific Stock Down 1.4 %

Thermo Fisher Scientific stock opened at $598.40 on Monday. The firm has a market capitalization of $228.89 billion, a price-to-earnings ratio of 36.20, a P/E/G ratio of 4.06 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a 50 day simple moving average of $541.37 and a 200 day simple moving average of $571.18.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.29 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.26%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.44%.

Thermo Fisher Scientific declared that its board has authorized a stock buyback program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 29,000 shares of company stock worth $15,859,540 in the last three months. Corporate insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.